0 CHECKOUT

Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2015

  • ID: 1196697
  • June 2015
  • Region: Global
  • Bioseeker

Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, there is plenty of room for more competition.
There are today 363 companies plus partners developing 609 PKI drugs in 2525 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 446 drugs. Protein Kinase Inhibitors In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 265 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 261 out of the 262 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed READ MORE >

Note: Product cover images may vary from those shown



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Amgen Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Novartis AG
  • Baxter International Inc.